Novo Nordisk to open Type 1 diabetes research and development center
PRINCETON, N.J. — In an effort to take Type 1 diabetes research to the next level, Novo Nordisk is set to open a research and development center in Seattle.
The center, slated to open this summer, will combine basic research and early proof-of-concept trials under one umbrella, the drug maker said. Additionally, the center will be staffed by approximately 20 researchers who will be supported by corporate functions in the United States and Denmark.
"Novo Nordisk has been passionate about helping people fight diabetes since the company was founded, and it is part of our mission to Take type 1 diabetes research to the next level," said Mads Krogsgaard Thomsen, EVP and chief science officer at Novo Nordisk. "With the new Type 1 diabetes R&D center, we hope to accelerate the process of finding new, innovative ways of treating people with this disease. Our vision is to prevent, treat and ultimately cure diabetes."